Gracell Biotechnologies  logo
Gracell Biotechnologies GRCL

Quarterly report 2022-Q2
added 08-15-2022

report update icon

Gracell Biotechnologies EPS Ratio 2011-2026 | GRCL

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Gracell Biotechnologies

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-1.38 -2.77 -2.03 -0.73 - - - - - - -

All numbers in CNY currency

Indicator range from annual reports

Maximum Minimum Average
-0.73 -2.77 -1.73

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-15.4 - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
-3.87 - 1052.0 % $ 415 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
241 $ 18.06 - $ 28.2 B japanJapan
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
2.1 $ 19.44 -0.46 % $ 909 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-0.07 - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
-1.91 - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-24.9 - - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
-2.38 - 1.93 % $ 17.4 M usaUSA
Akouos Akouos
AKUS
-2.52 - 0.23 % $ 488 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-3.75 - - $ 3.67 B usaUSA
I-Mab I-Mab
IMAB
-7.66 - - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
1.51 - 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
-1.77 - -0.23 % $ 916 M usaUSA
Biophytis SA Biophytis SA
BPTS
-0.26 - -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
-1.96 - 10.36 % $ 9.8 M usaUSA
Aptinyx Aptinyx
APTX
-0.96 - -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-31 - -18.52 % $ 27.3 M britainBritain
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
-10.1 - -6.81 % $ 3.04 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-0.36 - - $ 26.5 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-15.8 - -52.27 % $ 4.45 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-2.46 - - $ 7.46 M israelIsrael
Atreca Atreca
BCEL
-2.52 - -11.76 % $ 5.79 M usaUSA
Protara Therapeutics Protara Therapeutics
TARA
-1.34 $ 5.03 -3.08 % $ 215 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
-204 - -24.86 % $ 820 K usaUSA
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
-1.59 $ 67.0 -0.3 % $ 2.8 B usaUSA
bluebird bio bluebird bio
BLUE
-1.93 - - $ 546 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-0.79 - 4.01 % $ 150 M canadaCanada
Theravance Biopharma Theravance Biopharma
TBPH
1.2 $ 14.9 -1.91 % $ 750 M cayman-islandsCayman-islands
Avid Bioservices Avid Bioservices
CDMO
-2.23 - - $ 789 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-6.62 - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-1.66 - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
-7.99 - -9.65 % $ 45.9 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-0.86 $ 1.2 -6.97 % $ 306 M britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
0.2 - 0.49 % $ 251 B cayman-islandsCayman-islands
Bio-Techne Corporation Bio-Techne Corporation
TECH
0.47 $ 51.31 -2.65 % $ 8.08 B usaUSA
Tenax Therapeutics Tenax Therapeutics
TENX
-1.34 $ 14.64 -2.2 % $ 574 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
0.85 - -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
-2.19 - -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
-1.89 - - $ 3.74 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
-0.73 $ 1.07 -2.29 % $ 21.9 M israelIsrael
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
1.23 $ 28.76 -3.43 % $ 32.9 B israelIsrael
Enochian Biosciences Enochian Biosciences
ENOB
-1.08 - - $ 40.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-2.21 - - $ 867 M germanyGermany
Equillium Equillium
EQ
-0.39 $ 2.03 -1.46 % $ 116 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
-0.17 $ 23.81 1.51 % $ 641 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-2.08 - -74.18 % $ 955 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
-6.47 $ 46.38 -2.45 % $ 4.17 B schweizSchweiz